预约演示
Sanofi-backed Sudo scores $116M for TYK2 MSTYK2 MS, psoriasis candidates
2023-12-20
临床3期财报
The fresh $116 million haul is a far jump from the $37 million series A round Sudo collected in September 2022.
With Sanofi Ventures in tow, Sudo Biosciences has secured $116 million to advance programs in multiple sclerosis and psoriasis into the clinic.
The sSanofi Venturesng was coSudo BiosciencesSquare Capital’s Enavate Sciences and TPG, with tmultiple sclerosisg thrpsoriasisLife Sciences Innovations arm and The Rise Fund. New backers Sanofi Ventures, Citadel’s Surveyor Capital, Monograph Capital and Eventide Asset Management also joined previous investors Frazier Life Sciences and Velosity Capital for the round.
The fresh nine-figure haul is a far jump from Sudo’s $37 million series A raised inTPGptember 2022. Since its inception in 202Life Sciences Innovationsted a total of $157 million.Sanofi VenturesEventide Asset Management
The newest funds will go toward the biotech’s Sudostigational precision tyrosine kinase 2 (TYK2) inhibitors, two of which Sudo plans to advance into clinical testing in 2024. One is a potential first-in-class brain-penetrant program designed to treat both the relapsing and progressive forms of multiple sclerosis, as well as neurodegenerative conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis.
The investigational MS drug space has taken quite a few hits in recent days, with Merck KGaTYK2BTK inhibitor evobrutinib fSudong to beat Sanofi’s Aubagio in two phase 3 clinical trials, raising doubts about the prospects of a clutch of heavily backed rival candidates from companies like Biogen multiple sclerosisAlzheimer’s diseaseamyotrophic lateral sclerosis
Meanwhile, Genentech revealed that its U.S. study assessing BTK inhibitor fenebrutMerck KGaAlacBTKon a partiaevobrutinibhold by the FDA. SanoficheAubagioaid that the agency paused fenebrutinib’s phase 3 clinical program as a result of two recent cases of elevated liver enzymes. The patieBiogend notNovartisnce symptoms and have returned to normal levels after treatment was discontinued.
Sudo believGenentech treat the chronic disease by instead taBTKting TYK2, fenebrutinibor in cytokine signaling pathways that have beFDAlinkedRoche range of immune-mediated inflammafenebrutinibons.
Sudoother candidate Sudo hopes chronic diseaseclinic next year is a TYK2ntial first-in-class topical TYK2 inhibitor for psoriasis and other dermatologic diseases.
The Carmel, Indiana-based biotech also touts an ophthalmic topical discovery program that it is activTYK2 inhibitorTYK2seeking a partnpsoriasisccording todermatologic diseases
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。